Document Type
Article
Publication Date
1-1-2008
Abstract
BACKGROUND: Endorepellin, the C-terminal domain V of the heparan sulfate proteoglycan perlecan, exhibits powerful and targeted anti-angiogenic activity on endothelial cells. To identify proteins involved with endorepellin anti-angiogenic action, we performed an extensive comparative proteomic analysis between vehicle- and endorepellin-treated human endothelial cells. RESULTS: Proteomic analysis of endorepellin influence on human umbilical vein endothelial cells identified five differentially expressed proteins, three of which (beta-actin, calreticulin, and chaperonin/Hsp60) were down-regulated and two of which (vimentin and the beta subunit of prolyl 4-hydroxylase also known as protein disulfide isomerase) were up-regulated in response to endorepellin treatment-and associated with a fold change (endorepellin/control) /= 2.00, and a statistically significant p-value as determined by Student's t test. CONCLUSION: The proteins identified represent potential target areas involved with endorepellin anti-angiogenic mechanism of action. Further elucidation as such will ultimately provide useful in utilizing endorepellin as an anti-angiogenic therapy in humans.
Recommended Citation
Zoeller, Jason J and Iozzo, Renato V, "Proteomic profiling of endorepellin angiostatic activity on human endothelial cells." (2008). Department of Pathology, Anatomy and Cell Biology Faculty Papers. Paper 47.http://jdc.jefferson.edu/pacbfp/47
Comments
This article has been peer reviewed and is published in BMC Proteome Science Volume 6, 12 February 2008, Article number 7. The published version is available at DOI: 10.1186/1477-5956-6-7. Copyright © BioMed Central Ltd.